THARIMMUNE INC (THAR) Stock Fundamental Analysis

NASDAQ:THAR • US4327053090

4.74 USD
+0.26 (+5.8%)
At close: Feb 17, 2026
4.8255 USD
+0.09 (+1.8%)
After Hours: 2/17/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to THAR. THAR was compared to 521 industry peers in the Biotechnology industry. THAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. THAR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year THAR has reported negative net income.
  • THAR had a negative operating cash flow in the past year.
  • THAR had negative earnings in each of the past 5 years.
  • In the past 5 years THAR always reported negative operating cash flow.
THAR Yearly Net Income VS EBIT VS OCF VS FCFTHAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -134.03%, THAR is not doing good in the industry: 81.38% of the companies in the same industry are doing better.
  • THAR's Return On Equity of -167.66% is on the low side compared to the rest of the industry. THAR is outperformed by 65.83% of its industry peers.
Industry RankSector Rank
ROA -134.03%
ROE -167.66%
ROIC N/A
ROA(3y)-179.85%
ROA(5y)-342.76%
ROE(3y)-395.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THAR Yearly ROA, ROE, ROICTHAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • THAR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THAR Yearly Profit, Operating, Gross MarginsTHAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, THAR has more shares outstanding
  • Compared to 5 years ago, THAR has more shares outstanding
  • THAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
THAR Yearly Shares OutstandingTHAR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
THAR Yearly Total Debt VS Total AssetsTHAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • THAR has an Altman-Z score of 58.11. This indicates that THAR is financially healthy and has little risk of bankruptcy at the moment.
  • THAR's Altman-Z score of 58.11 is amongst the best of the industry. THAR outperforms 96.55% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that THAR is not too dependend on debt financing.
  • THAR has a Debt to Equity ratio (0.03) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 58.11
ROIC/WACCN/A
WACCN/A
THAR Yearly LT Debt VS Equity VS FCFTHAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

  • A Current Ratio of 4.98 indicates that THAR has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.98, THAR is in line with its industry, outperforming 56.05% of the companies in the same industry.
  • THAR has a Quick Ratio of 4.98. This indicates that THAR is financially healthy and has no problem in meeting its short term obligations.
  • THAR has a Quick ratio (4.98) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 4.98
THAR Yearly Current Assets VS Current LiabilitesTHAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • THAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.73%, which is quite impressive.
EPS 1Y (TTM)77.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 41.09% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.23%
EPS Next 2Y41.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THAR Yearly EPS VS EstimatesTHAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • THAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year THAR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THAR Price Earnings VS Forward Price EarningsTHAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THAR Per share dataTHAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as THAR's earnings are expected to grow with 41.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.09%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for THAR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

THARIMMUNE INC

NASDAQ:THAR (2/17/2026, 8:00:02 PM)

After market: 4.8255 +0.09 (+1.8%)

4.74

+0.26 (+5.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners3.2%
Inst Owner Change847.93%
Ins Owners0.98%
Ins Owner Change0%
Market Cap178.84M
Revenue(TTM)N/A
Net Income(TTM)-10.32M
Analysts82.86
Price Target5.1 (7.59%)
Short Float %8.83%
Short Ratio2.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 29.06
P/tB 29.06
EV/EBITDA N/A
EPS(TTM)-4.11
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -134.03%
ROE -167.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.85%
ROA(5y)-342.76%
ROE(3y)-395.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 4.98
Altman-Z 58.11
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.28%
EPS Next Y5.23%
EPS Next 2Y41.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.67%
OCF growth 3YN/A
OCF growth 5YN/A

THARIMMUNE INC / THAR FAQ

Can you provide the ChartMill fundamental rating for THARIMMUNE INC?

ChartMill assigns a fundamental rating of 2 / 10 to THAR.


What is the valuation status of THARIMMUNE INC (THAR) stock?

ChartMill assigns a valuation rating of 1 / 10 to THARIMMUNE INC (THAR). This can be considered as Overvalued.


Can you provide the profitability details for THARIMMUNE INC?

THARIMMUNE INC (THAR) has a profitability rating of 0 / 10.


Can you provide the financial health for THAR stock?

The financial health rating of THARIMMUNE INC (THAR) is 5 / 10.